Candidate Troy Jackson Held Event With Vertex Lobbyists
Maine Senate candidate Troy Jackson met with lobbyists for Vertex Pharmaceuticals at a Portland campaign event.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do you trust a candidate who campaigns against lobbyists while maintaining personal ties to them?
Maine Senate candidate Troy Jackson appeared at a campaign event in Portland alongside lobbyists representing Vertex Pharmaceuticals. The lobbyists, Kate Knox and Alysia Melnick, have represented the drug manufacturer since 2024.
Why it matters
The appearance highlights intersections between political candidates and high-revenue corporate interests. It arrives as questions persist regarding drug manufacturer policy changes that affect patient access to medication.
Vertex Pharmaceuticals generated $12 billion in revenue in 2025 while reducing its annual copay assistance for the drug Orkambi from approximately $100,000 to $20,000.
The players
Troy Jackson
He is a candidate for the Maine Senate who previously served as the president of the Maine Senate in 2024.
Kate Knox
She is a lobbyist who has represented Vertex Pharmaceuticals since 2024 and previously served as legal counsel for various Maine political figures.
Alysia Melnick
She is a professional lobbyist who began representing Vertex Pharmaceuticals in 2024 alongside her firm partners.
Vertex Pharmaceuticals
This is a biotechnology company headquartered in Boston that generated $12 billion in revenue in 2025.
The details
The lobbyists, Kate Knox and Alysia Melnick, were identified through a facial recognition search at the September 27 event in Portland. Knox previously provided legal representation for Troy Jackson during a 2017 case concerning Maine's ranked-choice voting law.
Timeline
Kate Knox represented Troy Jackson in a 2017 legal case.
Knox and Alysia Melnick began representing Vertex Pharmaceuticals in 2024.
The campaign event involving Jackson took place on September 27, 2026.
The Tech Race
The involvement of lobbyists in the candidate's campaign follows a pattern established during the 2017 Maine ranked-choice voting law case where the same lobbyist represented the candidate. This signals how long-term professional relationships in the state influence modern political access.
Changes to drug copay assistance programs, such as the reduction for Orkambi, directly impact the out-of-pocket costs for patients relying on these medications. Residents monitoring this race may consider how lobbyist ties could shape future legislative oversight of pharmaceutical pricing.
The takeaway
Voters often benefit from examining the professional history and current affiliations of those seeking public office. Understanding the intersection between lobbyists and candidates can provide clarity on how future policy decisions might be influenced.
Further reading
Learn more about the latest industry developments in the Biotech section.
Source note: This article includes information reported by Washington Free Beacon.
Live Poll
Do you trust a candidate who campaigns against lobbyists while maintaining personal ties to them?
